Stanazolol--an anabolic steroid that does not influence parathyroid hormone response to hypercalcemia in postmenopausal women
| Autor: | I. Žofková, S. Röjdmark, R. L. Kancheva |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
endocrine system
medicine.medical_specialty Time Factors medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Osteoporosis Radioimmunoassay Parathyroid hormone Administration Oral Endocrinology Anabolic Agents Internal medicine medicine Humans Orthopedics and Sports Medicine Testosterone Stanozolol Osteoporosis Postmenopausal Calcium metabolism Dose-Response Relationship Drug business.industry Estrogens Luteinizing Hormone Middle Aged medicine.disease Postmenopause medicine.anatomical_structure Estrogen Parathyroid Hormone Hypercalcemia Parathyroid gland Calcium Female business hormones hormone substitutes and hormone antagonists Anabolic steroid medicine.drug |
| Zdroj: | Calcified tissue international. 54(6) |
| ISSN: | 0171-967X |
| Popis: | Estrogen influences the calcium-induced suppressibility of parathyroid hormone (PTH) in postmenopausal women. We tested the hypothesis that parathyroid gland function is also sensitive to the anabolic steroid, stanazolol. The calcium-induced suppressibility of PTH was investigated in 11 osteoporotic postmenopausal women on two occasions, before and after 1 month's oral treatment with stanazolol. Compliance to treatment was checked by the determination of serum luteinizing hormone (LH) and testosterone. Serum intact PTH and ionized calcium were estimated before and 5, 60, and 120 minutes after I.V. calcium load. Calcium-induced PTH suppression was of a similar magnitude before and after stanazolol, although calcium increments were identical. The results imply that stanazolol--at biologically effective doses--does not affect PTH responsiveness to hypercalcemia in postmenopausal women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink